Double-Blind Follow-On Safety Study of HZT-501 (Ibuprofen 800 mg/Famotidine 26.6 mg)in Subjects Who Have Completed Participation in Horizon Protocol HZ-CA-301 (NCT00450658)or Horizon Protocol HZ-CA-303 (NCT00450216)

Trial Profile

Double-Blind Follow-On Safety Study of HZT-501 (Ibuprofen 800 mg/Famotidine 26.6 mg)in Subjects Who Have Completed Participation in Horizon Protocol HZ-CA-301 (NCT00450658)or Horizon Protocol HZ-CA-303 (NCT00450216)

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Dec 2014

At a glance

  • Drugs Ibuprofen/famotidine (Primary) ; Ibuprofen
  • Indications Musculoskeletal pain; NSAID-induced ulcer; Osteoarthritis; Rheumatoid arthritis
  • Focus Adverse reactions
  • Acronyms REDUCE-1; REDUCE-2
  • Sponsors Horizon Pharma
  • Most Recent Events

    • 03 Nov 2010 Results will be presented at the 74th Annual Scientific Meeting of the American College of Rheumatology and the 45th Annual Meeting of the Association of Rheumatology and Health Professionals, according to an Horizon Pharma media release.
    • 29 Jan 2008 Addition of sponsor and trial centre.
    • 29 Jan 2008 Status changed from initiated to recruiting from NCT last updated 29 Jan 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top